Thank you! We will get back to you shortly.

Future of Cell & Gene Therapy for Life Sciences Hybrid Event


Date: 9th June, 2022
Time - 12 PM GMT / 7 AM ET
Location - Mercure Hotel, Amsterdam


Overview of Future of Cell & Gene Therapy for Life Sciences

Cell and gene therapy provide an almost limitless source of new ideas. These treatments are personalised and have the potential to be useful for a variety of illnesses. The COVID-19 pandemic highlighted how the pharmaceutical sector can work together to achieve a major goal like vaccine development in a short amount of time. While cell and gene therapies (CGTs) have the potential to revolutionise oncology and other critical diseases therapy, the industry must first overcome enormous cultural and systemic constraints.

To introduce desired sequence alterations, current gene-editing technologies use nuclease-based systems to cut DNA strands and trigger DNA repair mechanisms. Multiple waves of next-generation editing technologies are queued up on the heels of these efforts to increase specificity, precision, efficiency, and applicability to other types of disease, even though these technologies are only now beginning to be tested clinically. The breakthroughs of base editing and prime editing, for example, have made it possible to precisely alter genomic sequences in the absence of DNA breaks and without relying on the activity of endogenous DNA repair processes.

Leaning toward these technologies will result in future cell and gene therapy facilities that can pivot fast in a global health context where flexibility and efficiency are valued highly. The COVID-19 pandemic has revealed a concerning lack of readiness to move quickly from clinical vaccination testing to large-scale manufacturing.

The cell and gene therapy sector is booming, as it is with many new ecosystems, with thorough reviews of many diseases, formats, and technology. We may expect a more focused focus on R & D activities as this field evolves and is reinforced by even more scientific evidence, allowing these therapies to mature.

To provide more insight and detailed analysis into the future of this industry, Group Futurista is happy to present its “Future of Cell & Gene Therapy for Life Sciences”, with revolutionary keynotes, case studies, and more.

What to Expect?


Connect, listen and learn with our highly informative keynote sessions, panel discussions, fireside chats etc.

Panel Discussions

Conversations and deliberations that are contagious


Connect with leading key-decision makers & tech solution providers across the industry

Webinar Highlights

07+ Knowledge Sessions

The summit will consist of interesting web panel discussions, exclusive live fireside chats and engaging digital industry presentations. 

10+ Industry

Industry’s leading experts, key-decision makers and solution providers will gather to discuss latest trends & technologies of Cell & Gene Therapy.


Congregation of industry's top-level executives and senior officials for knowledge sharing.

Discussion Points

The cell and gene therapy market of the future: Monopoly or polyopoly?

Cell and Gene Therapies: From Concept to Commercialization

Manufacturing Challenges facing Cell & Gene Therapy

Novel Single-use Solutions for Cell & Gene Therapy Manufacturing

Topic We Cover

Gene Augmentation

Gene Inhibition

Gene Therapy Manufacturing

Cellular Therapy

Cellular Neuroscience

Cellular Neuropathology

Non-Neuronal Cells

Cellular Neurophysiology


Antisense Therapy


DNA‐Templated Organic Synthesis

DNA Vaccination

Epigenome Editing

Synthetic Lethality

Synthetic Rescue

Therapeutic Gene Modulation

Cell Encapsulation



Life Science and Biology


Who should attend?

Job Titles

CXO, VP, Director, Head, Manager, Specialist of

  • Genomic Data Engineering
  • Discovery Strategy Portfolio
  • Molecular Toxicology
  • CMC Cell and Gene Therapy
  • Preclinical and Translational Medicine
  • Pharmacology & Toxicology
  • Discovery Research
  • Antibody Engineering
  • Molecular and Genomic Assays
  • Translational Medicine
  • Screening & Compound Profiling
  • Drug Design
  • R&D Licensing
  • Principal Scientist
  • Function Genomics
  • Drug Discovery
  • Pharmacology
  • Target Discovery & Assessment


Kinshuk Saxena

Associate Director - Commercialization Strategy & Operations, Novartis

Albert Ribickas

Supervisor Cell Therapy Facility, Moffitt Cancer Center

Tamie Joeckel

Global Business Lead, Cell and Gene Therapy COE at ICON plc

Jonas Dreyer Kristensen

Global Associate Director Cell Therapy Commercial Unit at Nova Nordisk

Jurriaan de Vink

Assistant Scientist
Johnson & Johnson

Kartoosh Heydari

Director of FACS Facility, Associate Scientific Director of IND development, Cell Therapy Facility, Stanford Healthcare

Clare Hague

Senior Director, Therapy Area Market Access Leader, Hematology (EMEA) at The Janssen Pharmaceutical Companies of Johnson & Johnson

Our Sponsors

Gold Sponsor


Media Partners


Frequently asked question

Absolutely. We are counting on you to invite others! Help us spread the word. You can simply share the link to this page, and they can register at their convenience.